secwatch.observer — SEC 8-K summary
======================================

Issuer:     PRECIGEN, INC. (PGEN)
CIK:        0001356090
Form:       8-K
Filed at:   2023-04-05T23:59:59+00:00
Accession:  0000950103-23-005425
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Precigen enters amended license with Alaunos for TCR products; Alaunos pays $75K annual fee
--------------------------------------------------------------------------------

- Precigen grants Alaunos exclusive, worldwide, royalty-free license for T-cell receptor products targeting neoantigens and HPV.
- Alaunos also gets exclusive license for Sleeping Beauty technology for TCR products for neoantigens and shared antigens.
- Alaunos pays $75,000 annual license fee; no milestones or royalties on products.
- Alaunos loses rights to IL-12, CAR (CD-19, BCMA), and Gorilla IL-12 products; Precigen retains those.
- Precigen may develop products outside the exclusive license; Alaunos can terminate on country/program basis.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1356090/000095010323005425/0000950103-23-005425-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1356090/000095010323005425/dp191956_8k.htm
  HTML page:      https://secwatch.observer/filing/0000950103-23-005425

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer